$MDXG I think we will see a run up to restate. It is obvious what happened. Mimedx was channel stuffing, short ran with that but grossly exaggerated other issues which resulted in lower stock price. The stock has come back from 1 when it became clear they weren’t going bankrupt. Now it’s clear they are moving forward with restatement and relisting so we are heading to 8 or maybe 9 or 10 after relist. Up from there is pipeline. The pipeline is likely going to pay off all you need to do is look at the data that’s out there, it’s public information. Once the data starts coming in it will continue up next year.
  • 3
  • 5